- Home
- GPRO vs MDWD Comparison
GPRO vs MDWD Comparison
Compare GPRO & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GPRO
- MDWD
- Stock Information
- Founded
- GPRO 2004
- MDWD 2000
- Country
- GPRO United States
- MDWD Israel
- Employees
- GPRO N/A
- MDWD N/A
- Industry
- GPRO Industrial Machinery/Components
- MDWD Medicinal Chemicals and Botanical Products
- Sector
- GPRO Consumer Discretionary
- MDWD Health Care
- Exchange
- GPRO Nasdaq
- MDWD Nasdaq
- Market Cap
- GPRO 193.5M
- MDWD 184.8M
- IPO Year
- GPRO 2014
- MDWD 2014
- Fundamental
- Price
- GPRO $0.97
- MDWD $19.45
- Analyst Decision
- GPRO Hold
- MDWD Strong Buy
- Analyst Count
- GPRO 1
- MDWD 1
- Target Price
- GPRO $1.50
- MDWD $25.00
- AVG Volume (30 Days)
- GPRO 1.6M
- MDWD 78.0K
- Earning Date
- GPRO 02-06-2025
- MDWD 03-20-2025
- Dividend Yield
- GPRO N/A
- MDWD N/A
- EPS Growth
- GPRO N/A
- MDWD N/A
- EPS
- GPRO N/A
- MDWD N/A
- Revenue
- GPRO $896,011,000.00
- MDWD $19,720,000.00
- Revenue This Year
- GPRO N/A
- MDWD $10.15
- Revenue Next Year
- GPRO N/A
- MDWD $25.62
- P/E Ratio
- GPRO N/A
- MDWD N/A
- Revenue Growth
- GPRO N/A
- MDWD N/A
- 52 Week Low
- GPRO $0.89
- MDWD $11.04
- 52 Week High
- GPRO $3.03
- MDWD $24.00
- Technical
- Relative Strength Index (RSI)
- GPRO 22.61
- MDWD 55.03
- Support Level
- GPRO $1.03
- MDWD $19.59
- Resistance Level
- GPRO $1.04
- MDWD $20.62
- Average True Range (ATR)
- GPRO 0.04
- MDWD 0.83
- MACD
- GPRO -0.01
- MDWD 0.02
- Stochastic Oscillator
- GPRO 0.85
- MDWD 54.60
About GPRO GoPro Inc.
GoPro Inc is a United States-based company that is principally engaged in designing and providing cameras, mounts, drones and appliances. The company outsources a part of manufacturing to third parties in China. The company sells products across the world through its direct sales channel, which generates over half of total revenue, and indirectly through its distribution channel. The company has presence, including in the Americas, Europe, Middle East, Africa, and Asia-Pacific, with the Americas contributing over half of total revenue.
About MDWD MediWound Ltd.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.